No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/β0-thalassaemia

European Journal of Haematology

Volumn 84, Issue 1, 2010, Pages 59-63

  Ghoti, Hussam ^a   Goitein, Orly ^b   Koren, Ariel ^c,d   Levin, Carina ^c,d   Kushnir, Tamar ^b   Rachmilewitz, Eliezer ^a   Konen, Eli ^b  

^a WOLFSON MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Free iron; Iron overload; Myocardial; Sickle 0 thalassaemia

Indexed keywords

DEFEROXAMINE; FERRITIN; HEPCIDIN; HYDROXYUREA; IRON; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE EXACERBATION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HEART; HEART LEFT VENTRICLE FAILURE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PRIORITY JOURNAL; SICKLE CELL BETA THALASSEMIA; SICKLE CELL CRISIS; SPLENECTOMY; SYSTOLIC DYSFUNCTION; TRANSFERRIN BLOOD LEVEL;

ADULT; ANEMIA, SICKLE CELL; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-THALASSEMIA; BLOOD TRANSFUSION; FEMALE; HUMANS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; PANCREAS; YOUNG ADULT;

EID: 72449186172     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01355.x     Document Type: Article

References (26)

1. 0-thalassaemia. Am J Hematol 2005 80 : 70 4.
2. 0-thalassaemia patients. Br J Haematol 2004 124 : 385 390.
3. Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006 91 : 1388 1391.
4. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009 82 : 454.
5. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion dependent thalassaemia and sickle cell disease. Blood 2004 103 : 1934 1936.
6. Hershko C, Graham G, Bates GW, et al. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978 40 : 255 263.
7. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003 102 : 2670 2677.
8. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008 112 : 4292 4297.
9. Breuer W, Cabantchik ZI. A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 2001 299 : 194 202.
10. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001 22 : 2171 2179.
11. Mavrogeni SI, Gotsis ED, Markussis V, et al. T2 relaxation time study of iron overload in beta thalassaemia. Magma 1998 6 : 7 12.
12. 0-thalassaemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol 2007 17 : 1535 1543.
13. Wood J. Cardiac iron across different transfusion-dependent diseases. Blood Rev 2008 22 : S14 21.
14. Olivieri NF, Brittenham GM, Matsui D, et al. Iron chelation therapy with oral deferiprone in patients with thalassaemia major. N Engl J Med 1995 332 : 918 922.
15. Brownell A, Lowson S, Brozovic M. Serum ferritin concentration in sickle crisis. J Clin Pathol 1986 39 : 253 255.
16. Chirnomas SD, Geukes-Foppen M, Barry K, et al. Practical implications of liver and heart iron load assessment by T2*- MRI in children and adults with transfusion-dependent anemias. Am J Haematol 2008 83 : 781 783.
17. Vymazal J, Urgosik D, Bulte JW. Differentiation between hemosiderin and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol 2000 46 : 835 842.
18. 0-thalassaemia. Ann Hematol 2009 88 : 557 564.
19. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassemia and sickle cell disease. Br J Hematology 2004 126 : 736 742.
20. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998 850 : 227 231.
21. Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassaemia major. Am J Haematol 2008 84 : 29 33.
22. 0-thalassaemia or sickle cell disease. Br J Haematol 2006 135 : 254 263.
23. Walter PB, Knutson MD, Paler-Martines A, et al. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rates. Proc Natl Acad Sci USA 2002 99 : 2264 2269.
24. 0- thalassaemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferropoietin. Blood 2007 109 : 5027 5035.
25. Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006 91 : 809 812.
26. Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007 48 : 7 63.